Xiaoyan Chu - Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 109 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Characterization of Organic Anion Transporting Polypeptide (OATP)1B1 and OATP1B3 Humanized Rat As a Translational Model to Study the Pharmacokinetics of OATP1B Substrate Drugs

Yang Li,Jocelyn Yabut, Zuo Zhang, Scott Fauty, Robert Houle, Hannah Miller, Nanyan Rena Zhang, Myung K Shin, Thomas W Rosahl, Heather H Zhou,Bhagwat Prasad,Jashvant D Unadkat,Xiaoyan Chu

Drug metabolism and disposition the biological fate of chemicalsno. 7 (2025): 100101-100101

Cited0Views0WOSBibtex

Predicting OCT2/MATEs-Mediated Drug Interactions in Healthy Volunteers and Patients with Chronic Kidney Disease: Insights from Extended Clearance Concept, Endogenous Biomarkers, and in Vitro Inhibition Studies (perspectives from the International Transporter Consortium)

Satoshi Asano,Aleksandra Galetin, Yoshiko Tomita, Kathleen M Giacomini,Xiaoyan Chu,Xinning Yang, Toshimichi Nakamura,Hiroyuki Kusuhara,Yuichi Sugiyama

Clinical pharmacology and therapeutics (2025)

Cited0Views0WOSBibtex

Survey of Pharmaceutical Industry's Best Practices Around in Vitro Transporter Assessment and Implications for Drug Development: Considerations from the International Consortium for Innovation and Quality for Pharmaceutical Development Transporter Working Group

Drug Metabolism and Dispositionpp.DMD-001587, (2024)

Cited1Views0WOSBibtex

Effects of Cimetidine and Dolutegravir on the Endogenous Drug-Drug Interaction Biomarkers for Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Protein 1 in Healthy Volunteers

Tomoki Koishikawa, Kaku Fujiwara,Kunal Taskar,Maciej J. Zamek-Gliszczynski,Kenta Yoshida,Xiaoyan Chu,Hideki Hirabayashi,Jialin Mao,Kevin Rockich,Tadayuki Takashima,Yoshiyuki Yamaura,Yurong Lai, Yukana Tomoda,Tomoko Kito,Kazuya Maeda,Kenichi Furihata,Yuichi Sugiyama,Hiroyuki Kusuhara

Clinical pharmacology and therapeuticsno. 2 (2024): 523-533

Cited0Views0WOSBibtex

Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study (vol 46, pg 943, 2018)

B. Prasad, D. K. Bhatt, K. Johnson, R. Chapa,X. Chu,L. Salphati, G. Xiao, C. Lee,C. E. C. A. Hop, A. Mathias, Y. Lai, M. Liao, W. Humphreys,S. C. Kumer,J. D. Unadkat

DRUG METABOLISM AND DISPOSITIONno. 6 (2024): 580-580

Cited0Views0Bibtex

Evaluation of the Selectivity of Several Organic Anion Transporting Polypeptide 1B Biomarkers Using Relative Activity Factor Method

Grace Hoyee Chan,Robert Houle, Jinghui Zhang,Ravi Katwaru,Yang Li,Xiaoyan Chu

DRUG METABOLISM AND DISPOSITIONno. 9 (2023): 1089-1104

Cited9Views0WOSBibtex

Interlaboratory Variability in the Madin–Darby Canine Kidney Cell Proteome

Matthew D. Harwood,Katharina Zettl,Manuel Weinheimer,Venkatesh Pilla-Reddy,Hong Shen, Frank Jacobs,Xiaoyan Chu,Felix Huth,Masanori Nakakariya,Paresh P. Chothe,Sibylle Neuhoff,Jacek R. Wisniewski

MOLECULAR PHARMACEUTICSno. 7 (2023): 3505-3518

Cited2Views0WOSBibtex

Utilization of OATP1B Biomarker Coproporphyrin-I to Guide Drug-Drug Interaction Risk Assessment: Evaluation by the Pharmaceutical Industry

Ryota Kikuchi,Paresh P. Chothe,Xiaoyan Chu,Felix Huth,Kazuya Ishida,Naoki Ishiguro,Rongrong Jiang,Hong Shen,Simone H. Stahl,Manthena V. S. Varma,Marie-Emilie Willemin,Bridget L. Morse

CLINICAL PHARMACOLOGY & THERAPEUTICSno. 6 (2023): 1170-1183

Cited11Views0WOSBibtex

Coproporphyrin I As an Endogenous Biomarker to Detect Reduced OATP1B Activity and Shift in Elimination Route in Chronic Kidney Disease

Hiroyuki Takita,Daniel Scotcher,Xiaoyan Chu,Ka Lai Yee,Kayode Ogungbenro,Aleksandra Galetin

Clinical Pharmacology & Therapeuticsno. 3 (2022): 615-626

Cited13Views0WOSBibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn